Valuation: Adocia

Market Cap 82.96M 96.1M 77.83M 70.89M 133M 9.19B 135M 912M 358M 4.6B 361M 353M 15.31B P/E 2026 *
-774x
P/E 2027 * 6.13x
Enterprise Value 53.12M 61.53M 49.83M 45.39M 85.34M 5.88B 86.52M 584M 229M 2.95B 231M 226M 9.8B EV / Sales 2026 *
21.1x
EV / Sales 2027 * 3.2x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
1 week+3.74%
Current month+6.78%
1 month+9.84%
3 months-13.31%
6 months-38.48%
Current year-33.75%
1 week 4.01
Extreme 4.01
4.28
1 month 3.69
Extreme 3.694
4.28
3 years 3
Extreme 2.995
14.84
5 years 2.72
Extreme 2.725
14.84
10 years 2.72
Extreme 2.725
62.21
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 80 24/02/2012
Director/Board Member 58 18/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+3.74%-57.29%-47.18% 96.1M
+4.80%+3.44%+70.64%+109.32% 73.25B
-1.17%+12.76%+47.30%+88.23% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.42%+5.83%+56.97%+21.50% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+1.09%+6.42%+40.70%-13.60% 19.46B
+3.64%+2.55%+21.31%+556.97% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +1.33%+1.06%+44.17%+176.01% 30.79B
Weighted average by Cap. +1.69%+3.14%+54.59%+164.35%

Financials

2026 *2027 *
Net sales 2.52M 2.92M 2.37M 2.15M 4.05M 279M 4.11M 27.73M 10.87M 140M 10.97M 10.73M 465M 35.4M 41.01M 33.21M 30.25M 56.88M 3.92B 57.67M 389M 153M 1.96B 154M 151M 6.53B
Net income -4.32M -5M -4.05M -3.69M -6.94M -478M -7.03M -47.48M -18.61M -240M -18.77M -18.37M -797M -44.33M -51.35M -41.59M -37.88M -71.22M -4.91B -72.21M -488M -191M -2.46B -193M -189M -8.18B
Net Debt -29.84M -34.57M -28M -25.5M -47.95M -3.31B -48.61M -328M -129M -1.66B -130M -127M -5.51B 30.18M 34.95M 28.31M 25.79M 48.48M 3.34B 49.16M 332M 130M 1.67B 131M 128M 5.57B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
18/08/26 4.220 0.00%
17/08/26 €4.220 +2.28%
14/08/26 €4.126 -1.90%
13/08/26 €4.206 +2.99%
12/08/26 €4.084 -0.15%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.240EUR
Average target price
9.700EUR
Spread / Average Target
+128.77%

Quarterly revenue - Rate of surprise